Skip to content

A randomized controlled trial of internet-assisted Cognitive Behavioral Therapy for depression

A randomized controlled trial of internet-assisted Cognitive Behavioral Therapy for depression - i-CBT Study

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000009242
Enrollment
40
Registered
2012-11-01
Start date
2012-11-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Interventions

internet-assisted cognitive behavior therapy in addition to treatment as usual treatment as usual

Sponsors

i-CBT study group
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Subjects with current DSM-IV Major Depressive Disorder based on SCID at screening. 2.Subjects with HAMD-17 score>=14 at screening. 3.Subjects who had received at least adequate one trial of antidepressant therapy for more than 6weeks. 4.Aged 20 years or older, and younger than 65 years at screening. 5.Subjects who give full consent in the participation of the study. 6.Subjects who can be used to use the internet. 7.Subjects who have the possibility that they can go to the hospital more than 6 times during the study period.

Exclusion criteria

Exclusion criteria: 1.No alcohol or substance use disorder in 6 months prior to the screening. 2.No history or concurrent manic or psychotic episode. 3.No other primary DSM-IV Axis I Disorders at screening. 4.No comorbid of antisocial personality disorder. 5.No serious suicidal ideation at screening. 6.No past treatment of individual CBT. 7.No organic brain lesions or major cognitive deficits in a year prior to the screening. 8.No severe or unstable medical co-morbidities at screening. 9.Other relevant reason decided by the i-CBT principal investigator.

Design outcomes

Secondary

MeasureTime frame
Response rate(defined as 50% reduction of baseline HAMD-17),remission rate(defined as HAMD=<7),subjective depression(measured with the BDI and QIDS),quality of life(measured with EQ-5D and SF-36) and vulnerability measure of depression and cognition (DAS) at 12week and post-intervention phase(up to 6months) will be compared between the groups.Cost effectiveness (ICER per remitted patient and ICER per QALY) will be also compared between the groups.

Primary

MeasureTime frame
Hamilton Depression Rating Scale (HAMD-17) score at endpoint will be compared between the groups

Countries

Japan

Contacts

Public ContactYoshiyo Oguchi

National Center of Neurology & Psychiatry CBT Center

yoguchi1978@gmail.com042-341-2711

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026